A Study in MPS VI to Assess Safety and Efficacy of Odiparcil

NCT ID: NCT03370653

Last Updated: 2019-11-01

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 20 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2017-12-30
• Study Completion Date: 2019-10-22

Brief Summary

Mucopolysaccharidoses (MPS) are a group of rare inherited disorders characterized by a deficiency of lysosomal enzymes responsible for the normal degradation of glycosaminoglycans (GAGs). Medical need for treatment of MPS is still very high due to the poor penetration of the recombinant enzymes into the blood brain barrier as well as the ocular barriers and into tissues that are poorly vascularized, such as cartilages and bones. Odiparcil is an orally active compound that allows the synthesis of soluble glycosaminoglycans (GAGs), mainly chondroitin sulfate (CS) and dermatane sulfate (DS). The neosynthesized solubles GAGs are then excreted in urine. By diverting endogenous GAG synthesis to the synthesis of soluble odiparcil linked GAGs, odiparcil should decrease the intracellular pool of GAGs and consequently decrease the lysosomal GAG accumulation.

The primary objective of the study is to assess the safety and efficacy of two doses of odiparcil in MPS VI patients and to provide evidence to enable the selection of the relevant dose of odiparcil for phase III study. The secondary objective of this study is to characterize the dose response, PK and PD of odiparcil.

Detailed Description

Study design: This phase IIa study consists of 2 parts performed sequentially: a preliminary safety assessment followed by the core study with a double-blind, randomized, dose-ranged cohort of patients receiving Enzyme Replacement Therapy (ERT) and an open-label cohort of patients not receiving ERT.

Preliminary safety assessment (N=2): open-label, escalating dose (2 doses) study. If acceptable safety profile is achieved, patients will be then included in the open-label arm of the core study.

Core study

Core study will be conducted on 2 populations in parallel:

• A first cohort (N=18): MPS VI patients receiving ERT assigned in 3 arms:

• Placebo (N=6)
• Odiparcil 500 mg per day (250 mg BID) (N=6)
• Odiparcil 1000 mg per day (500 mg BID) (N=6).
• A second cohort (N=6): MPS VI patient not receiving ERT (odiparcil 1000 mg per day (500 mg BID)).

Study duration: The overall study duration will be 20 months, including the 10-month enrolment period.

For each patient, the study duration will be:

• Preliminary safety assessment: 6 weeks including a 4-week run-in period followed by 2-week treatment period. Then, patients will go on treatment period in core study.
• Core study: 34 weeks including a 4-week run-in period followed by 26-week treatment period and 4-week of follow-up.

Conditions

Mucopolysaccharidosis VI

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Open Label - odiparcil 1000 mg per day

2 tablets of odiparcil 250 mg per os, twice daily (BID)

Group Type: EXPERIMENTAL

Odiparcil

Intervention Type: DRUG

Investigational product: odiparcil 250 mg tablets

Double-blind - odiparcil 1000 mg per day

2 tablets of odiparcil 250 mg per os, twice daily (BID)

Group Type: EXPERIMENTAL

Odiparcil

Intervention Type: DRUG

Investigational product: odiparcil 250 mg tablets

Double-blind - odiparcil 500 mg per day

1 tablet of placebo and 1 tablet of odiparcil 250 mg per os, twice daily (BID)

Group Type: EXPERIMENTAL

Odiparcil

Intervention Type: DRUG

Investigational product: odiparcil 250 mg tablets

Placebo

Intervention Type: OTHER

Comparator: placebo tablets similar to odiparcil 250 mg tablets

Double-blind - placebo

2 tablets of placebo per os, twice daily (BID)

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: OTHER

Comparator: placebo tablets similar to odiparcil 250 mg tablets

Interventions

Odiparcil

Investigational product: odiparcil 250 mg tablets

Intervention Type: DRUG

Placebo

Comparator: placebo tablets similar to odiparcil 250 mg tablets

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

1. Patients with MPS Type VI receiving enzyme replacement therapy (Naglazyme) for at least 6 months on the licensed dosage or as per local guidelines.

Patients with MPS Type VI not receiving enzyme replacement therapy for the following reasons:

1. Patients previously treated with ERT but have discontinued for more than 3 months either due to medical decision or personal choice

2. Patients allergic to ERT therapy

3. Patients that have had a previous hematopoietic stem cell transplant (HSCT)

4. Patients not treated with ERT i.e. treatment naïve

Exclusion Criteria

1. Use of any investigational product or investigational medical device within 30 days prior to screening. This will include product bought over the counter specifically compounds like genistein and pentosane polysulphate which may not be considered as investigational products by patients and some health care professionals.

2. Concurrent disease or condition that would interfere with study participation or pose a safety concern for example patient with: severe cardiac insufficiency as define NYHA class > II, and severe restrictive chronic respiratory insufficiency as reflected by serum [HCO3-] ≥28 mEq/L.

3. Subjects who had surgery within 3 months before study starts, or for whom surgery is planned during study period.

4. Patient with spinal cord compression requiring surgical intervention.

5. Subjects with the following liver test anomalies: any ALT, AST > 3xULN or bilirubin >1.5xULN (except if Gilbert syndrome) at screening visit.

6. Evidence of an immunosuppressive state, including known HIV infection, agammaglubilinemias, T-Cell deficiencies.

7. Subjects with history of chronic infections, including but not limited to subjects with past history of viral hepatitis C, or B, with recent history of serious or life-threatening infection or any current signs or symptoms that may indicate infection at visit V-1 of study as per investigators clinical judgement.

8. History of malignant cancer except of cervical carcinoma in situ, basal cell carcinoma, dermatological squamous cell carcinoma.

9. Subjects with significant haematologic abnormalities, such as haemoglobin <8 g/dL, or WBC<2000 /mm3 or absolute neutrophil count <1300 /mm3, or platelet <30.000 /mm3.

10. International Normalized Ratio (INR), activated partial thromboplastin time (aPTT) or thrombin time (TT) values above the laboratory reference range at screening. For patients on anti-coagulants, they should be within their target effect on INR and be stable.

11. Any history of bleeding diathesis

12. Patient with coexistence of corneal pathologies other than corneal clouding (e.g. exposure keratopathy)

13. An unwillingness on the part of male patients to abstain from sexual intercourse with pregnant or lactating women; or an unwillingness to use highly effective form of birth control if engaging in sexual intercourse with a woman who could become pregnant from the time of the first dose of study medication until completion of follow-up procedures.

14. An unwillingness on the part of female patients to use highly effective form of birth control2 if engaging in sexual intercourse and to have a monthly pregnancy test during treatment and until completion of follow-up procedures.

15. Pregnant or lactating women.

16. Have a known hypersensitivity to any of the ingredients or excipients of the IMP including: Microcrystalline Cellulose, Povidone, Sodium starch glycolate (type A), Magnesium stearate, Opadry™ II 85F18422

1. Previous hematopoietic stem cell transplant (HSCT)

• Minimum Eligible Age: 16 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Inventiva Pharma

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Derralynn HUGHES, MD

Role: PRINCIPAL_INVESTIGATOR

Royal Free Hospital, London UK

Julia HENNERMANN, MD

Role: PRINCIPAL_INVESTIGATOR

Villa Metabolica, Mainz GERMANY

Nathalie GUFFON-FOUILHOUX, MD

Role: PRINCIPAL_INVESTIGATOR

Hôpital Femme-Mère-Enfant

Elisa LEAO-TELES, MD

Role: PRINCIPAL_INVESTIGATOR

Centro Hospitalar S. João, Porto, Portugal

Locations

Hôpital Femme-Mère-Enfant

Bron, , France

Villa Metabolica

Mainz, , Germany

Centro Hospitalar S. João

Porto, , Portugal

Royal Free Hospital

London, , United Kingdom

Countries

France; Germany; Portugal; United Kingdom

Other Identifiers

IVA_01_ODI_HMPS_17_002

Identifier Type: -

Identifier Source: org_study_id